Skip to content
Home/Companies/Biotech/GlycoVaxyn

GlycoVaxyn

Biotech·Switzerland·Exited 2015·Held 3yr
Entry
2012
Hold
3yr
Exit
2015

Who owns GlycoVaxyn?

GlycoVaxyn is a Swiss Biotech company, now owned by GSK, which acquired it in 2015 from Sofinnova Partners.

Hand-verified · updated 2026-09-30

Open JSON · CC-BY
Sofinnova Partners
Investor
Sofinnova Partners
Sofinnova Capital VII · 2012 · Life Sciences VC

Key facts

HQSwitzerland
SectorBiotech
Exit Type
Trade Sale
Buyer
GSK
Exit Year
2015

More from Sofinnova Capital VII

Other portfolio companies in the same fund.

Pixium Vision
Exited 2024
MedTechFrance· 2013
to Science Corporation
Advanced Perfusion Diagnostics
Exited 2019
MedTechFrance· 2012
to Vygon
Ascendis Pharma
Exited 2015
BiotechDenmark· 2012
EOS
Exited 2013
BiotechItaly· 2012
to Clovis Oncology

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns GlycoVaxyn?

GlycoVaxyn is now owned by GSK, which acquired it in 2015 from Sofinnova Partners.

When did GSK acquire GlycoVaxyn?

GSK acquired GlycoVaxyn in 2015, buying from Sofinnova Partners.

Who did GlycoVaxyn sell to?

Sofinnova Partners sold GlycoVaxyn to GSK in 2015 (Trade Sale).

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue